Mills-Peninsula’s Dr. Klonoff Presents on Artificial Pancreas, mHealth
In April 2013, nearly 200 scientists and clinicians from all over the world attended a conference called “Workshop on Innovation toward an Artificial Pancreas.” Among the physician researchers was David C. Klonoff, M.D., FACP, Fellow AIMBE, medical director of Mills-Peninsula’s Diabetes Research Institute.
New information on the current status of the artificial pancreas and the latest enabling technologies to advance this field was presented at the meeting. The purpose of the two-day conference was to have a multi-disciplinary discussion of advances and prospective areas of research that would accelerate the development and delivery of a wearable, automated artificial pancreas for individuals with diabetes.
Dr. Klonoff, was on the planning committee of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / U.S. Food and Drug Administration, and chaired a session on “New Developments in Modeling, Algorithms and Technology. He also spoke at the meeting on the topic of mHealth (mobile health), delivering health care via mobile devices such as smartphones and wearable body sensors.
“The artificial pancreas is becoming a reality,” Dr. Klonoff said. “There are many settings where this technology could be used and many levels of complexity for such devices to control blood glucose without input from patients. The safety and effectiveness of each product will need to be carefully tested and each product will need to be approved by the FDA. Systems and components currently under development both by companies and by independent investigators offer a great deal of promise for patients with diabetes,” he said.
Dr. Klonoff’s presentation covered how mobile communications devices, such as implanted or wearable sensors, smart phones, tablets, personal digital assistants and other wireless devices, are increasingly being used for health services. These devices can provide decision support and allow patients to track their health information and assist them to make some decisions.
The value of health apps is already being demonstrated; more than 40,000 mobile health applications have been developed and it has been estimated that nearly 250 million people have downloaded at least one health app.
Mills-Peninsula was the lead site on the first and recently completed United States multi-center outpatient trial of the first artificial pancreas system. Results from that study will be presented at the American Diabetes Association’s 73rd Scientific Sessions meeting in Chicago June 21-25, at McCormick Place, Chicago, Illinois.
The Mills-Peninsula Diabetes Research Institute is an internationally recognized research center which has helped to commercialize many new devices and drugs for patients with diabetes, including the first FDA approved dedicated diabetes telemedicine product.
Current studies show that uncontrolled diabetes creates intensified medical care requirements, high health care costs, and a high risk of disabling complications for diabetics. According to the NIDDK, it is expected that “physiological glucose-metabolic control provided by an artificial pancreas will reduce the incidence of acute and chronic complications and significantly improve the quality of life of the individuals affected. As a consequence, further morbidity and mortality also may be prevented.”
The Diabetes Research Institute at Mills-Peninsula is currently conducting trials on several innovative drugs and devices. People with diabetes interested in participating in a clinical trail can call 650-696-4261.
If you liked this article, you may also like:
New Study: Investigational Artificial Pancreas Device Safely Reduced Nighttime Hypoglycemia Diabetes Research Institute Reports Advances in 2012 UCSF, Mills-Peninsula Co-sponsor Diabetes Symposium & Kids’ Kamp